Pure Global

Value of PET/MR Enterography in the Assessment of Crohn's Disease Using a Collagen-binding Radiotracer. - Trial NCT06252493

Access comprehensive clinical trial information for NCT06252493 through Pure Global AI's free database. This phase not specified trial is sponsored by Massachusetts General Hospital and is currently Recruiting. The study focuses on Crohn Disease. Target enrollment is 25 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06252493
Recruiting
drug
Trial Details
ClinicalTrials.gov โ€ข NCT06252493
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Value of PET/MR Enterography in the Assessment of Crohn's Disease Using a Collagen-binding Radiotracer.
Evaluation of PET/MR Enterography for Differentiation of Fibrotic and Inflammatory Strictures in Patients With Crohn's Disease Using a Collagen-binding Radiotracer.

Study Focus

Crohn Disease

Radiotracer Injection

Observational

drug

Sponsor & Location

Massachusetts General Hospital

Charlestown, United States of America

Timeline & Enrollment

N/A

Dec 19, 2023

Dec 19, 2025

25 participants

Primary Outcome

Detection Rate of Fibrotic Strictures with [68Ga]CBP8-PET PET/MRE.

Summary

In this study twenty-five (25) subjects with Crohn's disease scheduled for possible surgical
 intervention will be recruited for this study and a PET/MR scan using the collagen-binding
 radiotracer will be performed. The study aims to establish the performance figures of PET/MR
 using [68Ga]CBP8-PET for preoperative detection and differentiation of strictures with a
 fibrotic component in patients with Crohn's disease by using surgical and histologic findings
 (when available) as the standard for comparison. Furthermore, the investigators will
 determine the performance figures with which strictures are identified and characterized by
 PET/MR using [68Ga]CBP8-PET compared to each modality in isolation (PET alone or MR alone).
 Blood and tissue markers for fibrostenosis will be explored (either predictive or as
 biomarkers for fibrotic burden), using histologic and molecular testing by using surgical and
 histologic findings (when available) as the standard for comparison. Lastly the investigators
 want to determine the performance figures with which strictures are identified and
 characterized by PET/MR using [68Ga]CBP8-PET compared to each modality in isolation (PET
 alone or MR alone).

ICD-10 Classifications

Crohn disease, unspecified
Other Crohn disease
Crohn disease of large intestine
Crohn disease of small intestine
Crohn disease [regional enteritis]

Data Source

ClinicalTrials.gov

NCT06252493

Non-Device Trial